DrugPatentWatch Database Preview
Otsuka Pharm Co Ltd Company Profile
What is the competitive landscape for OTSUKA PHARM CO LTD, and what generic alternatives to OTSUKA PHARM CO LTD drugs are available?
OTSUKA PHARM CO LTD has five approved drugs.
There are forty-eight US patents protecting OTSUKA PHARM CO LTD drugs.
There are seven hundred and ninety-seven patent family members on OTSUKA PHARM CO LTD drugs in forty-five countries and twenty-nine supplementary protection certificates in fourteen countries.
Summary for Otsuka Pharm Co Ltd
| International Patents: | 797 |
| US Patents: | 48 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Otsuka Pharm Co Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-004 | Jul 10, 2015 | RX | Yes | Yes | 10,307,419 | See Pricing | Y | See Pricing | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-006 | Nov 13, 2017 | RX | Yes | No | 8,961,412 | See Pricing | Y | See Pricing | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | RX | Yes | No | 9,320,455 | See Pricing | Y | See Pricing | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-005 | Nov 13, 2017 | RX | Yes | No | 8,718,193 | See Pricing | Y | See Pricing | |||
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-003 | Sep 29, 2014 | RX | Yes | No | 8,722,679 | See Pricing | Y | See Pricing | |||
| Otsuka Pharm Co Ltd | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-004 | Nov 13, 2017 | RX | Yes | No | 8,956,288 | See Pricing | Y | See Pricing | |||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-002 | Jul 10, 2015 | RX | Yes | No | 9,839,637 | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Otsuka Pharm Co Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-003 | Sep 29, 2014 | 5,006,528*PED | See Pricing |
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | 5,006,528*PED | See Pricing |
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-004 | Apr 23, 2018 | 5,972,882 | See Pricing |
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-005 | Apr 23, 2018 | 5,972,882 | See Pricing |
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-002 | Feb 28, 2013 | 5,006,528*PED | See Pricing |
| Otsuka Pharm Co Ltd | JYNARQUE | tolvaptan | TABLET;ORAL | 204441-002 | Apr 23, 2018 | 5,972,882 | See Pricing |
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-004 | Sep 29, 2014 | 5,006,528*PED | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Otsuka Pharm Co Ltd Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5300194 | See Pricing |
| Peru | 01242009 | See Pricing |
| Israel | 251640 | See Pricing |
| World Intellectual Property Organization (WIPO) | 2007028035 | See Pricing |
| Israel | 262761 | See Pricing |
| Israel | 251223 | See Pricing |
| Hong Kong | 1215397 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Otsuka Pharm Co Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1869025 | PA2018509,C1869025 | Lithuania | See Pricing | PRODUCT NAME: BREKSPIPRAZOLAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/18/1294 20180726 |
| 1675573 | 92427 | Luxembourg | See Pricing | PRODUCT NAME: ARIPIPRAZOLE |
| 1675573 | 239 5013-2014 | Slovakia | See Pricing | PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: EU/1/13/882/001 - EU/1/13/882/004 20131119 |
| 1675573 | 2014C/029 | Belgium | See Pricing | PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119 |
| 1869025 | 122018000088 | Germany | See Pricing | PRODUCT NAME: BREXPIPRAZOL ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1294 20180726 |
| 1869025 | 32/2018 | Austria | See Pricing | PRODUCT NAME: BREXPIPRAZOL ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1294 (MITTEILUNG) 20180727 |
| 1869025 | 1890028-2 | Sweden | See Pricing | PRODUCT NAME: BREXPIPRAZOLE, OR A SALT THEREOF; REG. NO/DATE: EU/1/18/1294 20180730 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
